Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review
Webb E. et al, (2022), BMJ Global Health, 7, e009838 - e009838
Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1.
Cheng H-Y. et al, (2022), Emerging infectious diseases, 28, 1559 - 1568
Perpetual Observational Studies: New strategies to support efficient implementation of observational studies and randomized trials in infectious diseases
Horby P., (2022), Clinical Microbiology and Infection
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.
Peto L. et al, (2022), Advances in biological regulation
A prototype lateral flow assay for detection of orthopoxviruses.
Ulaeto DO. et al, (2022), The Lancet. Infectious diseases
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Abani O. et al, (2022), The Lancet, 400, 359 - 368
Allocated but not treated: the silent 16% - Authors' reply.
Horby P. et al, (2022), Lancet (London, England), 399, 1775 - 1776
Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years.
van Beek J. et al, (2022), Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 27
Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission
Relph K. et al, (2022), Open Forum Infectious Diseases, 9
Innovations in public health surveillance: updates from a forum convened by the WHO Hub for Pandemic and Epidemic Intelligence, 2 and 3 February 2022.
Technical contributors to the Pandemic and Epidemic Intelligence Innovation Forum February meeting and report None., (2022), Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 27
Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.
Salam AP. et al, (2022), PLoS neglected tropical diseases, 16
The effect of hand hygiene frequency on reducing acute respiratory infections in the community: a meta-analysis.
Mo Y. et al, (2022), Epidemiology and infection, 150
Whole genome sequencing reveals host factors underlying critical Covid-19.
Kousathanas A. et al, (2022), Nature
COVID-19 can be called a treatable disease only after we have antivirals.
Zhang X. et al, (2022), Science bulletin
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2022), The Lancet, 399, 665 - 676
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15
Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number
Keeling MJ. et al, (2022), Statistical Methods in Medical Research, 096228022110702 - 096228022110702